



(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
03.09.2003 Bulletin 2003/36

(51) Int Cl.7: **C12N 15/19, C07K 14/475,
A61K 38/12**

(21) Application number: **95942271.8**

(86) International application number:
PCT/JP95/02708

(22) Date of filing: **27.12.1995**

(87) International publication number:
WO 96/020214 (04.07.1996 Gazette 1996/30)

(54) **TCF MUTANT**

TCF MUTANTE
MUTANT DE TCF

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB IE IT LI LU NL SE

(30) Priority: **27.12.1994 JP 33788594**

(43) Date of publication of application:
12.02.1997 Bulletin 1997/07

(60) Divisional application:
02077639.9 / 1 275 718

(73) Proprietor: **DAIICHI PHARMACEUTICAL CO., LTD.**
Chuo-ku, Tokyo 103-8234 (JP)

(72) Inventors:
• **KINOSAKI, Masahiko**
Shimotsuga-gun, Tochigi 329-05 (JP)
• **YAMAGUCHI, Kyoji**
Oomiya-shi, Saitama 330 (JP)
• **KOBAYASHI, Fumie**
Kawachi-gun, Tochigi 329-11 (JP)
• **GOTO, Masaaki**
Shimotsuga-gun, Tochigi 329-05 (JP)
• **MURAKAMI, Akihiko**
Shimotsuga-gun, Tochigi 321-02 (JP)
• **UEDA, Masatsugu**
Kawagoe-shi, Saitama 350-11 (JP)
• **HIGASHIO, Kanji**
Kawagoe-shi, Saitama 350 (JP)

• **YAMASHITA, Yasushi**
Shimotsuga-gun, Tochigi 329-05 (JP)

(74) Representative: **Wakerley, Helen Rachael**
Reddie & Grose,
16 Theobalds Road
London WC1X 8PL (GB)

(56) References cited:
WO-A-90/10651 WO-A-93/23541

• **MIZUNO K. ET AL.:** "Hairpin loop and second
Kring domain are essential sites for heparin
binding and biological activity of Hepatocyte
Growth Factor" J. BIOL. CHEM., vol. 269, no. 14,
14 January 1994, pages 1131-1136, XP002074886
• **NUCLEIC ACIDS RES.**, Vol. 10, No. 20, 1982, M.J.
ZOLLER et al., "Oligonucleotide-Directed
Mutagenesis Using M13-Derived Vectors", p.
6487-6500.
• **BIOCHEMISTRY**, Vol. 31, No. 4, 1992, J. LAWLER
et al., "Expression and Mutagenesis of
Thrombospondin", p. 1173-1180.
• **EUR. J. HAEMATOL.**, Vol. 47, No. 5, 1991, M.
DONNER et al., "An Arginine-545-Cysteine-545
Substitution Mutation of the Von Willebrand
Factor in Type IIB Von Willebrand's Disease", p.
342-345.

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).